KITAHARA Shiyuuji
   Department   Graduate School of Medical Science, Graduate School of Medical Science
   Position   Associate Professor (Fixed Term)
Article types Original article
Language English
Peer review Peer reviewed
Title Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients.
Journal Formal name：Cancers
Abbreviation：Cancers (Basel)
ISSN code：20726694/20726694
Domestic / ForeginForegin
Volume, Issue, Page 12(5),pp.E1275
Author and coauthor Duda Dan G, Dima Simona O, Cucu Dana, Sorop Andrei, Klein Sebastian, Ancukiewicz Marek, Kitahara Shuji, Iacob Speranta, Bacalbasa Nicolae, Tomescu Dana, Herlea Vlad, Tanase Cristiana, Croitoru Adina, Popescu Irinel
Publication date 2020/05
Summary Background: Improving surgical outcomes in hepatocellular carcinoma (HCC) patients would greatly benefit from biomarkers. Angiogenesis and inflammation are hallmarks of HCC progression and therapeutic targets. Methods: We retrospectively evaluated preoperative clinical variables and circulating (plasma) biomarkers of angiogenesis and inflammation in a cohort of HCC patients who underwent liver resection (LR) or transplantation (LT). Biomarker correlation with outcomes-freedom of liver recurrence (FLR), disease-free survival (DFS) and overall survival (OS)-was tested using univariate and multivariate Cox regression analyses. Results: Survival outcomes associated with sVEGFR1, VEGF and VEGF-C in LT patients and with IL-10 in LR patients. Moreover, in LT patients within Milan criteria, higher plasma VEGF and sVEGFR1 were associated with worse outcomes, while in those outside Milan criteria lower plasma VEGF-C associated with better outcomes. Multivariate analysis indicated that adding plasma VEGF or VEGF-C to a predictive model including Milan criteria and AFP improved prediction of DFS and OS (all p < 0.05). Conclusion: Survival outcomes after LR or LT differentially associated with angiogenic and inflammatory biomarkers. High plasma VEGF correlated with poorer prognosis within Milan criteria while low plasma VEGF-C associated with better prognosis outside Milan criteria. These candidate biomarkers should be further validated to improve patient stratification.
DOI 10.3390/cancers12051275
PMID 32443546